Medtech venture investors live up to their name
Fortunately for medical device start-ups, it takes more than a pandemic to put venture capitalists off doing deals.
Venture investors: biotech's preppers?
A handful of huge financings helped start-ups raise a record $5.4bn in the second quarter as investors brace for tougher times.
Biopharma venture investors shrug off Covid-19
First-quarter venture investments barely register the pandemic - huge cash reserves should protect funding for biotech start-ups this year.
Biopharma venture financing retreats, but not by much
Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.
How low can medtech venture investment go?
2019’s medtech VC total is swollen by the sector’s first $1bn round, but counterintuitively the amount going to smaller groups is increasing.
Venture cash gets even more concentrated
The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.
Private European companies enjoy their own treasure bath
The biotech financing scene in Europe continues to be dwarfed by the US, but on some measures the region is on an even footing.
Venture investing dips again for biopharma
The second quarter saw start-ups raise the smallest venture capital haul in two years, as the number of mega rounds declined.
Medtech VC and the billion-dollar era
The first one-shot billion-dollar venture investment round in the medical technology sector has gone to Verily as computing bleeds into medicine.
